Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-15T22:13:37.527Z Has data issue: false hasContentIssue false

50 - Palliation of fever and sweats: the heat is on!

Published online by Cambridge University Press:  04 August 2010

Donna S. Zhukovsky
Affiliation:
U.T. M.D. Anderson Cancer Center, Houston, USA
Michael J. Fisch
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Eduardo Bruera
Affiliation:
University of Texas, M. D. Anderson Cancer Center
Get access

Summary

Introduction

Almost all have experienced fever and the associated chills and sweats. Sweating also occurs independently of fever in various disease states, in normal situations like exercise and in common nondisease states such as menopause. Like other symptoms in advanced cancer, fever and sweats may be multifactorial, with different etiologies predominating at different points in the disease trajectory. Optimal management is predicated on an understanding of the contributing causes and pathophysiologic mechanisms, as well as knowledge of patient goals relative to the disease course.

Fever

Pathophysiology

In normal individuals, core body temperature is maintained within a tightly controlled range by a dynamic balance of heat production, heat conservation, and heat loss. There are three phases of fever. In the initiation phase, endogenous or exogenous pyrogens elevate the thermoregulatory set point above normal. Cutaneous vasoconstriction promotes heat retention and shivering produces additional heat. Behaviorally, the individual feels cold and seeks warmer clothing. When steady state fever is achieved, heat production balances heat loss and shivering ceases. During defervesence, the set point decreases to the normal core temperature and heat loss prevails. Heat loss occurs as a consequence of cutaneous vasodilation and sweating, with radiant and evaporative heat loss to the environment, respectively. There is a paucity of data describing the symptom complex associated with fever in the cancer patient.

Definition

Most oncologists consider a temperature in excess of 38.5 °C or 38 °C on three occasions at least 1 hour apart as clinically significant.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boggs, D R, Frei, E. Clinical studies of fever and infection in cancer. Cancer 1960;13:1240–533.0.CO;2-9>CrossRefGoogle Scholar
Briggs, L H. The occurrence of fever in malignant disease. Am J Med Sci 1923;166:846–53CrossRefGoogle Scholar
Klastersky, J, Weerts, D, Hensgens, C, Debusscher, L. Fever of unexplained origin in patients with cancer. Eur J Cancer 1973;9:649–56CrossRefGoogle ScholarPubMed
Loprinzi, C L, Michalak, J C, Quella, S K. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–52CrossRefGoogle ScholarPubMed
Loprinzi, C L, Kugler, J W, Sloan, J A. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63CrossRefGoogle ScholarPubMed
Quigley, C S, Baines, M. Descriptive epidemiology of sweating in a hospice population. J Palliat Care 1997;13:22–6Google Scholar
Steele, R W, Tanaka, P T, Lara, R P, Bass, J W. Evaluation of sponging and of oral antipyretic therapy to reduce fever. J Pediatr 1970;77:824–9CrossRefGoogle ScholarPubMed
Tsavaris, N, Zinelis, A, Karabelis, A. A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 1990;228:451–5CrossRefGoogle ScholarPubMed
Boulant J A. Thermoregulation. In Fever: Basic Mechanisms and Management, ed. P Mackowiak, pp. 1–22. New York: Raven Press, 1991
Clark W G. Antipyretics. In Fever: Basic Mechanics and Management, ed. P Mackowiak, pp. 297–340. New York: Raven Press, 1991
Cleary J F. Fever and sweats: including the immunocompromised hosts. In Principles and Practice of Supportive Oncology, ed. A Berger, R K Portenoy, D E Weissman, pp. 119–31. Philadelphia: Lippincott-Raven, 1998
Quesada, J R, Talpaz, M, Rios, A, Kurzrock, R, Gutterman, J U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234–43CrossRefGoogle ScholarPubMed
http://www.cancer.gov/cancerinfo/pdq/supportivecare/fever
Boggs, D R, Frei, E. Clinical studies of fever and infection in cancer. Cancer 1960;13:1240–533.0.CO;2-9>CrossRefGoogle Scholar
Briggs, L H. The occurrence of fever in malignant disease. Am J Med Sci 1923;166:846–53CrossRefGoogle Scholar
Klastersky, J, Weerts, D, Hensgens, C, Debusscher, L. Fever of unexplained origin in patients with cancer. Eur J Cancer 1973;9:649–56CrossRefGoogle ScholarPubMed
Loprinzi, C L, Michalak, J C, Quella, S K. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–52CrossRefGoogle ScholarPubMed
Loprinzi, C L, Kugler, J W, Sloan, J A. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–63CrossRefGoogle ScholarPubMed
Quigley, C S, Baines, M. Descriptive epidemiology of sweating in a hospice population. J Palliat Care 1997;13:22–6Google Scholar
Steele, R W, Tanaka, P T, Lara, R P, Bass, J W. Evaluation of sponging and of oral antipyretic therapy to reduce fever. J Pediatr 1970;77:824–9CrossRefGoogle ScholarPubMed
Tsavaris, N, Zinelis, A, Karabelis, A. A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 1990;228:451–5CrossRefGoogle ScholarPubMed
Boulant J A. Thermoregulation. In Fever: Basic Mechanisms and Management, ed. P Mackowiak, pp. 1–22. New York: Raven Press, 1991
Clark W G. Antipyretics. In Fever: Basic Mechanics and Management, ed. P Mackowiak, pp. 297–340. New York: Raven Press, 1991
Cleary J F. Fever and sweats: including the immunocompromised hosts. In Principles and Practice of Supportive Oncology, ed. A Berger, R K Portenoy, D E Weissman, pp. 119–31. Philadelphia: Lippincott-Raven, 1998
Quesada, J R, Talpaz, M, Rios, A, Kurzrock, R, Gutterman, J U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234–43CrossRefGoogle ScholarPubMed
http://www.cancer.gov/cancerinfo/pdq/supportivecare/fever

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×